Phase 2 study

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor AstraZeneca
Registry number NCT07115043
Started 29 July 2025 Today 16 October 2026 Estimated completion 2 October 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Research Site East Melbourne VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 120

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion criteria:

* Participant ≥ 18 year

* ECOG PS of 0 to 1

* Provision of 'archival' tumor specimen

* At least one measurable lesion according to RECIST v1.1,

* Minimum life expectancy of 12 weeks

* Adequate and stable cardiac function

* Adequate bone marrow, liver and kidney function

* Body weight ≥ 35 kg

* Capable of giving signed informed consent

Module 1 specific inclusion criteria:

• Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinoma of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancer/gastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC

Module 2 specific inclusion criteria:

* Participants with Stage IV NSCLC Dose Escalation/Backfills

1. Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR

2. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.

Dose Expansion

<!-- -->

1. Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.

Exclusion criteria:

* Any evidence of:

Severe or uncontrolled systemic diseases including respiratory, cardiac or tumor-related conditions

* History or planned organ or allogeneic stem cell transplantation.

* Active or prior documented autoimmune or inflammatory disorders, within the past 3 years

* Any prior toxicities that led to permanent discontinuation of prior immunotherapy

* Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy

* Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids

* Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis.

* Active uncontrolled or chronic infection of hepatitis B, hepatitis C

* Prior history of Grade ≥ 3 non-infectious pneumonitis.

* Participant requires chronic immunosuppressive therapy (including steroids \> 10 mg prednisone/day or equivalent).

* Receipt of live attenuated vaccine within 30 days.

Module 2 specific exclusion criteria:

* Previous treatment with anti-TIGIT therapy

* 1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC

Dates on the record

Started 29 July 2025
Estimated completion 2 October 2029
Registry last updated 8 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 8 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.